Bruce Allan Chabner is an American medical oncologist and researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His expansive research of cancer pharmacology most notably includes his contributions to developing anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.
He completed his undergraduate education at Yale University in 1961 and received his MD from Harvard Medical School in 1965.
Chabner entered the Public Health Service and started working at the National Cancer Institute (NCI) part of the National Institute of Health (NIH), where he studied under Joseph Bertino. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.[1] [2] He left the NIH in 1995 after 27 years at NCI and thirteen years as the director of the division of Cancer Treatment at NCI to join the faculty at Mass General Hospital as chief of hematology and oncology.[3]
He is the director of clinical research at the Cancer Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
Chabner grew up in Shelbyville, Illinois as the son of a general practitioner. He is married to Davi‐Ellen Rosenzweig and has two children and five grandchildren.